bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary figure and table legends from The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype
Authors: Linxweiler Maximilian , Kuo Fengshen , Katabi Nora , Lee Mark , Nadeem Zaineb , Dalin Martin G. , Makarov Vladimir , Chowell Diego , Dogan Snjezana , Ganly Ian , Hakimi A. Ari , Wong Richard J. , Riaz Nadeem , Ho Alan L. , Chan Timothy A. , Morris Luc G.T.
Published: April 2023

Supplementary figure and table legends
Figure S9 from The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype
Authors: Linxweiler Maximilian , Kuo Fengshen , Katabi Nora , Lee Mark , Nadeem Zaineb , Dalin Martin G. , Makarov Vladimir , Chowell Diego , Dogan Snjezana , Ganly Ian , Hakimi A. Ari , Wong Richard J. , Riaz Nadeem , Ho Alan L. , Chan Timothy A. , Morris Luc G.T.
Published: April 2023

Figure S9
Figure S6 from The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype
Authors: Linxweiler Maximilian , Kuo Fengshen , Katabi Nora , Lee Mark , Nadeem Zaineb , Dalin Martin G. , Makarov Vladimir , Chowell Diego , Dogan Snjezana , Ganly Ian , Hakimi A. Ari , Wong Richard J. , Riaz Nadeem , Ho Alan L. , Chan Timothy A. , Morris Luc G.T.
Published: April 2023

Figure S6
Supplementary Figures from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
Authors: Jaeger Alex M. , Stopfer Lauren , Lee Sunmin , Gaglia Giorgio , Sandel Demi , Santagata Sandro , Lin Nancy U. , Trepel Jane B. , White Forest , Jacks Tyler , Lindquist Susan , Whitesell Luke
Published: April 2023

Supplementary Figures S1-S5
Figure S12 from The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype
Authors: Linxweiler Maximilian , Kuo Fengshen , Katabi Nora , Lee Mark , Nadeem Zaineb , Dalin Martin G. , Makarov Vladimir , Chowell Diego , Dogan Snjezana , Ganly Ian , Hakimi A. Ari , Wong Richard J. , Riaz Nadeem , Ho Alan L. , Chan Timothy A. , Morris Luc G.T.
Published: April 2023

Figure S12
Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
Authors: Jaeger Alex M. , Stopfer Lauren , Lee Sunmin , Gaglia Giorgio , Sandel Demi , Santagata Sandro , Lin Nancy U. , Trepel Jane B. , White Forest , Jacks Tyler , Lindquist Susan , Whitesell Luke
Published: April 2023

PBMC RNAseq DESeq2 Data Tables
Supplementary Table 3 from Cancer-Stimulated CAFs Enhance Monocyte Differentiation and Protumoral TAM Activation via IL6 and GM-CSF Secretion
Authors: Cho Haaglim , Seo Youngha , Loke Kin Man , Kim Seon-Wook , Oh Seong-Min , Kim Jun-Hyeong , Soh Jihee , Kim Hyoen Sik , Lee Hyunju , Kim Jin , Min Jung-Joon , Jung Da-Woon , Williams Darren Reece
Published: April 2023

Primers used in this study
Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
Authors: Jaeger Alex M. , Stopfer Lauren , Lee Sunmin , Gaglia Giorgio , Sandel Demi , Santagata Sandro , Lin Nancy U. , Trepel Jane B. , White Forest , Jacks Tyler , Lindquist Susan , Whitesell Luke
Published: April 2023

MC38 Tumors Pan Cancer Immune Profiling Codeset
Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
Authors: Jaeger Alex M. , Stopfer Lauren , Lee Sunmin , Gaglia Giorgio , Sandel Demi , Santagata Sandro , Lin Nancy U. , Trepel Jane B. , White Forest , Jacks Tyler , Lindquist Susan , Whitesell Luke
Published: April 2023

PBMC RNAseq GO Analysis
Supplementary Table 1 from Cancer-Stimulated CAFs Enhance Monocyte Differentiation and Protumoral TAM Activation via IL6 and GM-CSF Secretion
Authors: Cho Haaglim , Seo Youngha , Loke Kin Man , Kim Seon-Wook , Oh Seong-Min , Kim Jun-Hyeong , Soh Jihee , Kim Hyoen Sik , Lee Hyunju , Kim Jin , Min Jung-Joon , Jung Da-Woon , Williams Darren Reece
Published: April 2023

Oncomine data
Supplemental Legend from Shortened Leukocyte Telomere Length Associates with an Increased Prevalence of Chronic Health Conditions among Survivors of Childhood Cancer: A Report from the St. Jude Lifetime Cohort
Authors: Song Nan , Li Zhenghong , Qin Na , Howell Carrie R. , Wilson Carmen L. , Easton John , Mulder Heather L. , Edmonson Michael N. , Rusch Michael C. , Zhang Jinghui , Hudson Melissa M. , Yasui Yutaka , Robison Leslie L. , Ness Kirsten K. , Wang Zhaoming
Published: April 2023

Supplemental Figure Legend
Supplementary Table 1 and Supplementary Figure Legends from Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers
Authors: Forrest Suzanne J. , Al-Ibraheemi Alyaa , Doan Duong , Ward Abigail , Clinton Catherine M. , Putra Juan , Pinches R. Seth , Kadoch Cigall , Chi Susan N. , DuBois Steven G. , Leavey Patrick J. , LeBoeuf Nicole R. , Mullen Elizabeth , Collins Natalie , Church Alanna J. , Janeway Katherine A.
Published: April 2023

Table S1 shows PD-L1, CD8 and CD163 staining in INI1-negative tumors
Supplementary Figure 3 from Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
Authors: Passaro Carmela , Alayo Quazim , DeLaura Isabel , McNulty John , Grauwet Korneel , Ito Hirotaka , Bhaskaran Vivek , Mineo Marco , Lawler Sean E. , Shah Khalid , Speranza Maria C. , Goins William , McLaughlin Eric , Fernandez Soledad , Reardon David A. , Freeman Gordon J. , Chiocca E. Antonio , Nakashima Hiroshi
Published: April 2023

In vivo comparison of scFvPD-1 production and viral gene expression in mouse and human GBM cells
Figure S1 from Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers
Authors: Forrest Suzanne J. , Al-Ibraheemi Alyaa , Doan Duong , Ward Abigail , Clinton Catherine M. , Putra Juan , Pinches R. Seth , Kadoch Cigall , Chi Susan N. , DuBois Steven G. , Leavey Patrick J. , LeBoeuf Nicole R. , Mullen Elizabeth , Collins Natalie , Church Alanna J. , Janeway Katherine A.
Published: April 2023

Figure S1 shows Tier 1-3 genomic events in INI1-negative tumors
Supplementary Figure 2 from Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
Authors: Passaro Carmela , Alayo Quazim , DeLaura Isabel , McNulty John , Grauwet Korneel , Ito Hirotaka , Bhaskaran Vivek , Mineo Marco , Lawler Sean E. , Shah Khalid , Speranza Maria C. , Goins William , McLaughlin Eric , Fernandez Soledad , Reardon David A. , Freeman Gordon J. , Chiocca E. Antonio , Nakashima Hiroshi
Published: April 2023

Engineering of NG34 to insert the sequence of the scFv against PD-1
Table S6 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Authors: Zhou Rong , Shi Chaoji , Tao Wenjie , Li Jiang , Wu Jing , Han Yong , Yang Guizhu , Gu Ziyue , Xu Shengming , Wang Yujue , Wang Lizhen , Wang Yanan , Zhou Guoyu , Zhang Chenping , Zhang Zhiyuan , Sun Shuyang
Published: April 2023

GISTIC peaks identified in MMs.
Supplementary Figure 1 from Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
Authors: Passaro Carmela , Alayo Quazim , DeLaura Isabel , McNulty John , Grauwet Korneel , Ito Hirotaka , Bhaskaran Vivek , Mineo Marco , Lawler Sean E. , Shah Khalid , Speranza Maria C. , Goins William , McLaughlin Eric , Fernandez Soledad , Reardon David A. , Freeman Gordon J. , Chiocca E. Antonio , Nakashima Hiroshi
Published: April 2023

Purification of the scFvPD-1 from HEK293 cells
Supplementary Table S2 from Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
Authors: Serrano César , Leal Alessandro , Kuang Yanan , Morgan Jeffrey A. , Barysauskas Constance M. , Phallen Jillian , Triplett Olivia , Mariño-Enríquez Adrián , Wagner Andrew J. , Demetri George D. , Velculescu Victor E. , Paweletz Cloud P. , Fletcher Jonathan A. , George Suzanne
Published: April 2023

Primer/probe mix for KIT-resistant mutations.
Supplementary Data from Serum- and Glucocorticoid-induced Kinase Sgk1 Directly Promotes the Differentiation of Colorectal Cancer Cells and Restrains Metastasis
Authors: Lee Lennard Y.W. , Woolley Connor , Starkey Thomas , Biswas Sujata , Mirshahi Tia , Bardella Chiara , Segditsas Stefania , Irshad Shazia , Tomlinson Ian
Published: April 2023

Supplementary Table 1. Differentially expressed genes from colonic crypt tops vs. bottoms of normal individuals (adjusted p<0.05). Supplementary Table 2. SGK1 expression of CRC cell lines from Broad Institute, The Cancer Cell Line Encyclopedia. Supplementary Table 3. Summary patient characteristics for sporadic CRC microarray. Supplementary Figure 1. Expression of SGK1 mRNA in normal colon (n=40), CRC (n=217) and CRC lines (n=7). Supplementary Figure 2. Average SGK1 expression levels resulting from the Tet-regulated, lentivirus-based system (qRT-PCR dCt values normalised to a GAPDH control). Supplementary Figure 3. SGK1 protein levels in representative anti-FLAG western blots of HT29 and LS174T cells transduced with FLAG-tagged SGK1-TetOff virus. Supplementary Figure 4. Increased levels of SGK1 induce degradation of the target protein Nedd4-2, confirming functionality of the transduced SGK1 protein. Supplementary Figure 5. Microscopic effects of re-expression of SGK1 in HT29 cells. Panels (a) to (d) show division of wild type cells (yellow arrows). Panels (e) to (h) show division of HT29 SGK1 re-expressing cells. Supplementary Figure 6. Representative images of immunofluorescence analysis showing ZO-1 and β-catenin expression in SGK1 re-expressing LS174T cells and controls. Supplementary Figure 7. Representative western blots demonstrating reduced MYC protein expression following SGK1 re-expression in SW480 (p=0.04, t test) Supplementary Figure 8. PKP3 induced by SGK1. Supplementary Figure 9. Effects of SGK1 on primary tumour growth and lung metastasis in an orthotopic transplant model Supplementary Figure 10. Representative immunohistochemistry section demonstrating SGK1 expression using EMD Millipore anti-SGK1 07-315. Supplementary Figure 11. Overall survival of CRC patients by SGK1 expression. Data are from The Cancer Genome Atlas, mRNAseq data (RSEM normalised)
Supplementary table 1 and 2 from Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy
Authors: Schoonderwoerd Mark J.A. , Koops Maaike F.M. , Angela Ricardo A. , Koolmoes Bryan , Toitou Melpomeni , Paauwe Madelon , Barnhoorn Marieke C. , Liu Yingmiao , Sier Cornelis F.M. , Hardwick James C.H. , Nixon Andrew B. , Theuer Charles P. , Fransen Marieke F. , Hawinkels Lukas J.A.C.
Published: April 2023

Supplementary table 1 and 2
Supplementary Figure 6 from Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers
Authors: Pozdeyev Nikita , Gay Laurie M. , Sokol Ethan S. , Hartmaier Ryan , Deaver Kelsi E. , Davis Stephanie , French Jena D. , Borre Pierre Vanden , LaBarbera Daniel V. , Tan Aik-Choon , Schweppe Rebecca E. , Fishbein Lauren , Ross Jeffrey S. , Haugen Bryan R. , Bowles Daniel W.
Published: April 2023

Genetic alterations in anaplastic thyroid cancer.
Supp Figure 1 from A Method to Summarize Toxicity in Cancer Randomized Clinical Trials
Authors: Carbini Mariana , Suárez-Fariñas Mayte , Maki Robert G.
Published: April 2023

All WTS data and CI by model
Table S1 from Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Authors: Gris-Oliver Albert , Palafox Marta , Monserrat Laia , Brasó-Maristany Fara , Òdena Andreu , Sánchez-Guixé Mònica , Ibrahim Yasir H. , Villacampa Guillermo , Grueso Judit , Parés Mireia , Guzmán Marta , Rodríguez Olga , Bruna Alejandra , Hirst Caroline S. , Barnicle Alan , de Bruin Elza C. , Reddy Avinash , Schiavon Gaia , Arribas Joaquín , Mills Gordon B. , Caldas Carlos , Dienstmann Rodrigo , Prat Aleix , Nuciforo Paolo , Razavi Pedram , Scaltriti Maurizio , Turner Nicholas C. , Saura Cristina , Davies Barry R. , Oliveira Mafalda , Serra Violeta
Published: April 2023

Percentage change in tumor volume in PDX per treatment and relevant PI3K/AKT/mTOR-pathway and TP53 mutations in PDX models
Table S2 from Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study
Authors: Posadas Edwin M. , Chi Kim N. , de Wit Ronald , de Jonge Maja J.A. , Attard Gerhardt , Friedlander Terence W. , Yu Margaret K. , Hellemans Peter , Chien Caly , Abrams Charlene , Jiao Juhui J. , Saad Fred
Published: April 2023

Duration of treatment exposure and PSA response since start of therapy for patients receiving systemic therapy with an AR signaling inhibitor prior to study entry
Figure S2 from Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study
Authors: Posadas Edwin M. , Chi Kim N. , de Wit Ronald , de Jonge Maja J.A. , Attard Gerhardt , Friedlander Terence W. , Yu Margaret K. , Hellemans Peter , Chien Caly , Abrams Charlene , Jiao Juhui J. , Saad Fred
Published: April 2023

Confirmed PSA response (as change from baseline) at any time for patients who received no prior therapy with AA-P or ENZ and patients who received therapy with AA-P only, ENZ only, or both AA-P and ENZ prior to study entry. Postbaseline PSA measurements were not available from two patients.
Figure S5 from Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Authors: Gris-Oliver Albert , Palafox Marta , Monserrat Laia , Brasó-Maristany Fara , Òdena Andreu , Sánchez-Guixé Mònica , Ibrahim Yasir H. , Villacampa Guillermo , Grueso Judit , Parés Mireia , Guzmán Marta , Rodríguez Olga , Bruna Alejandra , Hirst Caroline S. , Barnicle Alan , de Bruin Elza C. , Reddy Avinash , Schiavon Gaia , Arribas Joaquín , Mills Gordon B. , Caldas Carlos , Dienstmann Rodrigo , Prat Aleix , Nuciforo Paolo , Razavi Pedram , Scaltriti Maurizio , Turner Nicholas C. , Saura Cristina , Davies Barry R. , Oliveira Mafalda , Serra Violeta
Published: April 2023

Mechanisms of resistance to AZD5363 and paclitaxel pharmacokinetics
Figure S4 from Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Authors: Gris-Oliver Albert , Palafox Marta , Monserrat Laia , Brasó-Maristany Fara , Òdena Andreu , Sánchez-Guixé Mònica , Ibrahim Yasir H. , Villacampa Guillermo , Grueso Judit , Parés Mireia , Guzmán Marta , Rodríguez Olga , Bruna Alejandra , Hirst Caroline S. , Barnicle Alan , de Bruin Elza C. , Reddy Avinash , Schiavon Gaia , Arribas Joaquín , Mills Gordon B. , Caldas Carlos , Dienstmann Rodrigo , Prat Aleix , Nuciforo Paolo , Razavi Pedram , Scaltriti Maurizio , Turner Nicholas C. , Saura Cristina , Davies Barry R. , Oliveira Mafalda , Serra Violeta
Published: April 2023

Analysis of relevant signaling pathways, proliferation, apoptosis and S-phase entry in relation with AZD5363 resistance
Figure Legends from Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study
Authors: Posadas Edwin M. , Chi Kim N. , de Wit Ronald , de Jonge Maja J.A. , Attard Gerhardt , Friedlander Terence W. , Yu Margaret K. , Hellemans Peter , Chien Caly , Abrams Charlene , Jiao Juhui J. , Saad Fred
Published: April 2023

Figure legends for Figure S1 and Figure S2
Supplementary Tables from IFNL4-ΔG Allele Is Associated with an Interferon Signature in Tumors and Survival of African-American Men with Prostate Cancer
Authors: Tang Wei , Wallace Tiffany A. , Yi Ming , Magi-Galluzzi Cristina , Dorsey Tiffany H. , Onabajo Olusegun O. , Obajemu Adeola , Jordan Symone V. , Loffredo Christopher A. , Stephens Robert M. , Silverman Robert H. , Stark George R. , Klein Eric A. , Prokunina-Olsson Ludmila , Ambs Stefan
Published: April 2023

Supplementary Table 1. Characteristics of the African-American prostate cancer patients in the Cleveland Clinic Cohort according to overall survival; Supplementary Table 2. IRDS Probesets (n=49) for the Affymetrix U133A 2.0 array
Figure S2 from Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Authors: Gris-Oliver Albert , Palafox Marta , Monserrat Laia , Brasó-Maristany Fara , Òdena Andreu , Sánchez-Guixé Mònica , Ibrahim Yasir H. , Villacampa Guillermo , Grueso Judit , Parés Mireia , Guzmán Marta , Rodríguez Olga , Bruna Alejandra , Hirst Caroline S. , Barnicle Alan , de Bruin Elza C. , Reddy Avinash , Schiavon Gaia , Arribas Joaquín , Mills Gordon B. , Caldas Carlos , Dienstmann Rodrigo , Prat Aleix , Nuciforo Paolo , Razavi Pedram , Scaltriti Maurizio , Turner Nicholas C. , Saura Cristina , Davies Barry R. , Oliveira Mafalda , Serra Violeta
Published: April 2023

PIK3R1 mutation in head and neck squamous cell carcinoma (HNSCC) PDX and activation of AKT/mTORC1-pathway in two AKT1 p.E17K-mutant PDXs determine sensitivity to AZD5363
Supplementary Data from A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies
Authors: Rasco Drew W. , Papadopoulos Kyriakos P. , Pourdehnad Michael , Gandhi Anita K. , Hagner Patrick R. , Li Yan , Wei Xin , Chopra Rajesh , Hege Kristen , DiMartino Jorge , Shih Kent
Published: April 2023

Supplementary Table S1. Summary of avadomide plasma pharmacokinetic parameters by day and dose level Supplementary Figure S1. Representative flow cytometry analysis of Aiolos degradation in peripheral B cells (A) and T cells (B). Supplementary Figure S2. IL-2 expression correlates with Aiolos degradation in treated primary human T cells in vitro.
Supplementary Tables from Aberrant Thyroid-Stimulating Hormone Receptor Signaling Increases VEGF-A and CXCL8 Secretion of Thyroid Cancer Cells, Contributing to Angiogenesis and Tumor Growth
Authors: Song Young Shin , Kim Min Joo , Sun Hyun Jin , Kim Hwan Hee , Shin Hyo Shik , Kim Young A. , Oh Byung-Chul , Cho Sun Wook , Park Young Joo
Published: April 2023

Supplementary Table S1. Nucleotide sequences of primers used for quantitative RT-PCR Supplementary Table S2. Associations of VEGF-A with tumor angiogenesis, macrophage infiltration, and CXCL8 expression and associations among serum TSH levels, VEGF-A, and tumor size in 35 human papillary thyroid cancer tumors larger than 2cm in size
Supplementary Figures from Aberrant Thyroid-Stimulating Hormone Receptor Signaling Increases VEGF-A and CXCL8 Secretion of Thyroid Cancer Cells, Contributing to Angiogenesis and Tumor Growth
Authors: Song Young Shin , Kim Min Joo , Sun Hyun Jin , Kim Hwan Hee , Shin Hyo Shik , Kim Young A. , Oh Byung-Chul , Cho Sun Wook , Park Young Joo
Published: April 2023

Supplementary Fig. S1. TSH-independent growth of poorly-differentiated thyroid cancer cells. Supplementary Fig. S2. Expression of thyroid differentiation-related genes in thyroid cancer cell lines and effects of TSH on PAX-8 expression in BHP10-3SCp cells. Supplementary Fig. S3. Western blot analysis of the effect of TSH on VEGFR2 expression in PDTC tumors. *P< 0.05 versus controls. All data are expressed as mean {plus minus}SD. Supplementary Fig. S4. Effects of TSH on tumor growth and angiogenesis in a mouse tumor model of PDTC with FRO cell line. Supplementary Fig. S5. Effects of methimazole-induced hypothyroidismon tumor growth and angiogenesis in a PDTC mouse model. Supplementary Fig. S6. Effects of TSH on endothelial cells in cancer microenvironments. Supplementary Fig. S7. Direct effects of TSH on macrophage recruitment in poorly-differentiated thyroid cancer.
Supplementary Data from Aberrant Thyroid-Stimulating Hormone Receptor Signaling Increases VEGF-A and CXCL8 Secretion of Thyroid Cancer Cells, Contributing to Angiogenesis and Tumor Growth
Authors: Song Young Shin , Kim Min Joo , Sun Hyun Jin , Kim Hwan Hee , Shin Hyo Shik , Kim Young A. , Oh Byung-Chul , Cho Sun Wook , Park Young Joo
Published: April 2023

Supplementary Materials and Methods
Supplementary Table from Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients
Authors: Osti Daniela , Del Bene Massimiliano , Rappa Germana , Santos Mark , Matafora Vittoria , Richichi Cristina , Faletti Stefania , Beznoussenko Galina V. , Mironov Alexandre , Bachi Angela , Fornasari Lorenzo , Bongetta Daniele , Gaetani Paolo , DiMeco Francesco , Lorico Aurelio , Pelicci Giuliana
Published: April 2023

Table S3
Supplementary Data from Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients
Authors: Osti Daniela , Del Bene Massimiliano , Rappa Germana , Santos Mark , Matafora Vittoria , Richichi Cristina , Faletti Stefania , Beznoussenko Galina V. , Mironov Alexandre , Bachi Angela , Fornasari Lorenzo , Bongetta Daniele , Gaetani Paolo , DiMeco Francesco , Lorico Aurelio , Pelicci Giuliana
Published: April 2023

Supplementary Figures and Tables Captions
Supplementary Data from Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients
Authors: Osti Daniela , Del Bene Massimiliano , Rappa Germana , Santos Mark , Matafora Vittoria , Richichi Cristina , Faletti Stefania , Beznoussenko Galina V. , Mironov Alexandre , Bachi Angela , Fornasari Lorenzo , Bongetta Daniele , Gaetani Paolo , DiMeco Francesco , Lorico Aurelio , Pelicci Giuliana
Published: April 2023

Figure S1
Supplementary Table S2 from Whole-Exome Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma
Authors: Pareja Fresia , Brown David N. , Lee Ju Youn , Da Cruz Paula Arnaud , Selenica Pier , Bi Rui , Geyer Felipe C. , Gazzo Andrea , da Silva Edaise M. , Vahdatinia Mahsa , Stylianou Anthe A. , Ferrando Lorenzo , Wen Hannah Y. , Hicks James B. , Weigelt Britta , Reis-Filho Jorge S.
Published: April 2023

Supplementary Table S2 shows the non-synonymous somatic mutations identified in synchronous DCIS and IDC-NSTs subjected to whole-exome sequencing or MSK-IMPACT targeted massively parallel sequencing and/or targeted amplicon sequencing.
Supplementary Table S1 from Whole-Exome Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma
Authors: Pareja Fresia , Brown David N. , Lee Ju Youn , Da Cruz Paula Arnaud , Selenica Pier , Bi Rui , Geyer Felipe C. , Gazzo Andrea , da Silva Edaise M. , Vahdatinia Mahsa , Stylianou Anthe A. , Ferrando Lorenzo , Wen Hannah Y. , Hicks James B. , Weigelt Britta , Reis-Filho Jorge S.
Published: April 2023

Supplementary Table S1 shows the sequencing statistics of tumor and matched normal samples of the DCIS and IDC-NSTs subjected to whole-exome or targeted capture massively parallel sequencing.
Supplementary Methods from Whole-Exome Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma
Authors: Pareja Fresia , Brown David N. , Lee Ju Youn , Da Cruz Paula Arnaud , Selenica Pier , Bi Rui , Geyer Felipe C. , Gazzo Andrea , da Silva Edaise M. , Vahdatinia Mahsa , Stylianou Anthe A. , Ferrando Lorenzo , Wen Hannah Y. , Hicks James B. , Weigelt Britta , Reis-Filho Jorge S.
Published: April 2023

Supplementary Methods shows additional materials and methodology used in this study.
Supplementary Figure S1 from Whole-Exome Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma
Authors: Pareja Fresia , Brown David N. , Lee Ju Youn , Da Cruz Paula Arnaud , Selenica Pier , Bi Rui , Geyer Felipe C. , Gazzo Andrea , da Silva Edaise M. , Vahdatinia Mahsa , Stylianou Anthe A. , Ferrando Lorenzo , Wen Hannah Y. , Hicks James B. , Weigelt Britta , Reis-Filho Jorge S.
Published: April 2023

Supplementary Figure S1 shows the schematic representation of the samples, sequencing methods and analyses employed in this study.
Figure S4 from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
Authors: Wainberg Zev A. , Hochster Howard S. , Kim Edward J. , George Ben , Kaylan Aparna , Chiorean E. Gabriela , Waterhouse David M. , Guiterrez Martin , Parikh Aparna , Jain Rishi , Carrizosa Daniel Ricardo , Soliman Hatem H. , Lila Thomas , Reiss David J. , Pierce Daniel W. , Bhore Rafia , Banerjee Sibabrata , Lyons Larry , Louis Chrystal U. , Ong Teng Jin , O'Dwyer Peter J.
Published: April 2023

T-Cell Tumor Infiltration in Tissue-Matched Baseline (screening) and On-Treatment Metastatic Tumors (arm B parts 1 and 2)
Figure S3. Peripheral T-Cell Proliferation on Treatment (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
Authors: Wainberg Zev A. , Hochster Howard S. , Kim Edward J. , George Ben , Kaylan Aparna , Chiorean E. Gabriela , Waterhouse David M. , Guiterrez Martin , Parikh Aparna , Jain Rishi , Carrizosa Daniel Ricardo , Soliman Hatem H. , Lila Thomas , Reiss David J. , Pierce Daniel W. , Bhore Rafia , Banerjee Sibabrata , Lyons Larry , Louis Chrystal U. , Ong Teng Jin , O'Dwyer Peter J.
Published: April 2023

Percentage lymphocyte subset Ki67+. All patient visits are binned by treatment cycle. Data at baseline and treatment cycle 3 were compared using the Wilcoxon signed rank test. All available data are illustrated; however, statistical comparisons were performed only for data available at both baseline and treatment cycle 3 (n=29).
Supplementary Video Clips VCS1+2 and Optical Datsets ODS1+2 from PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma
Authors: Holst Frederik , Werner Henrica M.J. , Mjøs Siv , Hoivik Erling A. , Kusonmano Kanthida , Wik Elisabeth , Berg Anna , Birkeland Even , Gibson William J. , Halle Mari K. , Trovik Jone , Cherniack Andrew D. , Kalland Karl-Henning , Mills Gordon B. , Singer Christian F. , Krakstad Camilla , Beroukhim Rameen , Salvesen Helga B.
Published: April 2023

Links to supplementary video clips (VCS1+VCS2) and description of supplementary optical datasets (ODS1+ODS2)
Supplementary Tables from PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma
Authors: Holst Frederik , Werner Henrica M.J. , Mjøs Siv , Hoivik Erling A. , Kusonmano Kanthida , Wik Elisabeth , Berg Anna , Birkeland Even , Gibson William J. , Halle Mari K. , Trovik Jone , Cherniack Andrew D. , Kalland Karl-Henning , Mills Gordon B. , Singer Christian F. , Krakstad Camilla , Beroukhim Rameen , Salvesen Helga B.
Published: April 2023

Supplementary Tables
Supplementary Figure 4 from Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial
Authors: Weathers Shiao-Pei , Penas-Prado Marta , Pei Be-Lian , Ling Xiaoyang , Kassab Cynthia , Banerjee Pinaki , Bdiwi Mustafa , Shaim Hila , Alsuliman Abdullah , Shanley Mayra , de Groot John F. , O'Brien Barbara J. , Harrison Rebecca , Majd Nazanin , Kamiya-Matsuoka Carlos , Fuller Gregory N. , Huse Jason T. , Chi Linda , Rao Ganesh , Weinberg Jeffrey S. , Lang Frederick F. , Sawaya Raymond , Shpall Elizabeth J. , Rezvani Katayoun , Heimberger Amy B.
Published: April 2023

Supplementary Figure 4
Supplementary Table 4 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia
Authors: Verbeke Delphine , Demeyer Sofie , Prieto Cristina , de Bock Charles E. , De Bie Jolien , Gielen Olga , Jacobs Kris , Mentens Nicole , Verhoeven Bronte Manouk , Uyttebroeck Anne , Boeckx Nancy , De Keersmaecker Kim , Maertens Johan , Segers Heidi , Cools Jan
Published: April 2023

ChIP-seq data for NR3C1 bound genes
Supplementary Figure 9 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
Authors: Wang Yifan , Park Jin Yong Patrick , Pacis Alain , Denroche Robert E. , Jang Gun Ho , Zhang Amy , Cuggia Adeline , Domecq Celine , Monlong Jean , Raitses-Gurevich Maria , Grant Robert C. , Borgida Ayelet , Holter Spring , Stossel Chani , Bu Simeng , Masoomian Mehdi , Lungu Ilinca M. , Bartlett John M.S. , Wilson Julie M. , Gao Zu-Hua , Riazalhosseini Yasser , Asselah Jamil , Bouganim Nathaniel , Cabrera Tatiana , Boucher Louis-Martin , Valenti David , Biagi James , Greenwood Celia M.T. , Polak Paz , Foulkes William D. , Golan Talia , O'Kane Grainne M. , Fischer Sandra E. , Knox Jennifer J. , Gallinger Steven , Zogopoulos George
Published: April 2023

Supplementary Figure 9 shows the Cox proportional hazards model, integrating Moffitt transcriptomic subtype, tumour ploidy, stage and age
Supplementary Figure 1 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia
Authors: Verbeke Delphine , Demeyer Sofie , Prieto Cristina , de Bock Charles E. , De Bie Jolien , Gielen Olga , Jacobs Kris , Mentens Nicole , Verhoeven Bronte Manouk , Uyttebroeck Anne , Boeckx Nancy , De Keersmaecker Kim , Maertens Johan , Segers Heidi , Cools Jan
Published: April 2023

Suppl. figure 1: Doxorubicin and vincristine are not synergistic with KPT-8602 in diminishing proliferation of B-ALL and T-ALL
Supplementary Figure 6 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
Authors: Wang Yifan , Park Jin Yong Patrick , Pacis Alain , Denroche Robert E. , Jang Gun Ho , Zhang Amy , Cuggia Adeline , Domecq Celine , Monlong Jean , Raitses-Gurevich Maria , Grant Robert C. , Borgida Ayelet , Holter Spring , Stossel Chani , Bu Simeng , Masoomian Mehdi , Lungu Ilinca M. , Bartlett John M.S. , Wilson Julie M. , Gao Zu-Hua , Riazalhosseini Yasser , Asselah Jamil , Bouganim Nathaniel , Cabrera Tatiana , Boucher Louis-Martin , Valenti David , Biagi James , Greenwood Celia M.T. , Polak Paz , Foulkes William D. , Golan Talia , O'Kane Grainne M. , Fischer Sandra E. , Knox Jennifer J. , Gallinger Steven , Zogopoulos George
Published: April 2023

Supplementary Figure 6 shows the tumour ploidy analysis of xenografts evaluated in the preclinical trial that were not whole genome sequenced
Supplementary Figure 5 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
Authors: Wang Yifan , Park Jin Yong Patrick , Pacis Alain , Denroche Robert E. , Jang Gun Ho , Zhang Amy , Cuggia Adeline , Domecq Celine , Monlong Jean , Raitses-Gurevich Maria , Grant Robert C. , Borgida Ayelet , Holter Spring , Stossel Chani , Bu Simeng , Masoomian Mehdi , Lungu Ilinca M. , Bartlett John M.S. , Wilson Julie M. , Gao Zu-Hua , Riazalhosseini Yasser , Asselah Jamil , Bouganim Nathaniel , Cabrera Tatiana , Boucher Louis-Martin , Valenti David , Biagi James , Greenwood Celia M.T. , Polak Paz , Foulkes William D. , Golan Talia , O'Kane Grainne M. , Fischer Sandra E. , Knox Jennifer J. , Gallinger Steven , Zogopoulos George
Published: April 2023

Supplementary Figure 5 shows the immunohistochemical analysis of apoptotic activity in xenografts treated with gemcitabine mono- and combination therapies
Supplemental Figure 3 from Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Authors: Kyriakopoulos Christos E. , Eickhoff Jens C. , Ferrari Anna C. , Schweizer Michael T. , Wargowski Ellen , Olson Brian M. , McNeel Douglas G.
Published: April 2023

Supplementary Figure 3: IgG immunological response: IgG responses to AR LBD protein (panel A), PSA protein (panel B), and tetanus toxoid (panel C) were evaluated by Luminex. Sera samples were assessed at a 1:100 dilution from the time points indicated. Data were plotted over time, subtracting the pre-treatment value to evaluate change in post-treatment specimens.
Supplemental Figure 2 from Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Authors: Kyriakopoulos Christos E. , Eickhoff Jens C. , Ferrari Anna C. , Schweizer Michael T. , Wargowski Ellen , Olson Brian M. , McNeel Douglas G.
Published: April 2023

Supplementary Figure 2: T-cell immunological response to tetanus toxoid over time: Panel A: IFNγ ELISPOT data, similar to that as shown in Figure 3, were plotted over time, subtracting the pre-treatment value, to evaluate the magnitude and durability of immunity over time. Panel B: Immune response over time was plotted as "area under the curve," and evaluated with respect to treatment arm. Lines show median and interquartile range.
Supplementary Figure 10 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
Authors: Wang Yifan , Park Jin Yong Patrick , Pacis Alain , Denroche Robert E. , Jang Gun Ho , Zhang Amy , Cuggia Adeline , Domecq Celine , Monlong Jean , Raitses-Gurevich Maria , Grant Robert C. , Borgida Ayelet , Holter Spring , Stossel Chani , Bu Simeng , Masoomian Mehdi , Lungu Ilinca M. , Bartlett John M.S. , Wilson Julie M. , Gao Zu-Hua , Riazalhosseini Yasser , Asselah Jamil , Bouganim Nathaniel , Cabrera Tatiana , Boucher Louis-Martin , Valenti David , Biagi James , Greenwood Celia M.T. , Polak Paz , Foulkes William D. , Golan Talia , O'Kane Grainne M. , Fischer Sandra E. , Knox Jennifer J. , Gallinger Steven , Zogopoulos George
Published: April 2023

Supplementary Figure 10 shows multiplex IHC staining of the Q70P pancreatic resection specimen
Supplementary figure S3 from Multimodal CEA-Targeted Image-Guided Colorectal Cancer Surgery using 111In-Labeled SGM-101
Authors: de Gooyer Jan Marie , Elekonawo Fortuné M.K. , Bos Desirée L. , van der Post Rachel S. , Pèlegrin André , Framery Bérénice , Cailler Françoise , Vahrmeijer Alexander L. , de Wilt Johannes H.W. , Rijpkema Mark
Published: April 2023

Microscopic analysis of resected intraperitoneal tumors shows clear overlap of CEA-expressing tumor cells, NIR-fluorescence and radiosignal. In the bottom right corner a region with normal non-CEA expressing cells clearly shows low fluorescence and radiosignal. (A) H&E, B) CEA, C) NIR-Fluorescence, D) Autoradiography.
Supplementary Figure 1 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
Authors: Wang Yifan , Park Jin Yong Patrick , Pacis Alain , Denroche Robert E. , Jang Gun Ho , Zhang Amy , Cuggia Adeline , Domecq Celine , Monlong Jean , Raitses-Gurevich Maria , Grant Robert C. , Borgida Ayelet , Holter Spring , Stossel Chani , Bu Simeng , Masoomian Mehdi , Lungu Ilinca M. , Bartlett John M.S. , Wilson Julie M. , Gao Zu-Hua , Riazalhosseini Yasser , Asselah Jamil , Bouganim Nathaniel , Cabrera Tatiana , Boucher Louis-Martin , Valenti David , Biagi James , Greenwood Celia M.T. , Polak Paz , Foulkes William D. , Golan Talia , O'Kane Grainne M. , Fischer Sandra E. , Knox Jennifer J. , Gallinger Steven , Zogopoulos George
Published: April 2023

Supplementary Figure 1 shows the results of the Disambiguate algorithm used to assign the PDAC xenograft RNAseq reads to individual species
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Authors: Byrd John C. , Furman Richard R. , Coutre Steven E. , Flinn Ian W. , Burger Jan A. , Blum Kristie , Sharman Jeff P. , Wierda William , Zhao Weiqiang , Heerema Nyla A. , Luan Ying , Liu Emily A. , Dean James P. , O'Brien Susan
Published: April 2023

Supplementary Fig. S2: Overall survival in the following subgroups: (A) by number of prior lines of therapy; (B) by complex karyotype with del(17p) and without del(17p) in the relapsed/refractory setting; (C) with and without lymphocytosis at 1 year; (D) with and without lymphocytosis at 2 years; (E) CR/PR or PR-L within the first 364 days on study; (F) by age
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Authors: Byrd John C. , Furman Richard R. , Coutre Steven E. , Flinn Ian W. , Burger Jan A. , Blum Kristie , Sharman Jeff P. , Wierda William , Zhao Weiqiang , Heerema Nyla A. , Luan Ying , Liu Emily A. , Dean James P. , O'Brien Susan
Published: April 2023

Supplementary Fig. S3: All-grade AEs collected per protocol prior to June 2012 protocol amendment (median time on treatment 16 months) and grade 3 or higher or other specified AEs collected subsequent to amendment
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Authors: Byrd John C. , Furman Richard R. , Coutre Steven E. , Flinn Ian W. , Burger Jan A. , Blum Kristie , Sharman Jeff P. , Wierda William , Zhao Weiqiang , Heerema Nyla A. , Luan Ying , Liu Emily A. , Dean James P. , O'Brien Susan
Published: April 2023

Supplementary Fig. S4: Grade 3 or higher AEs of clinical interest by time to onset from first dose in the (A) first-line and (B) relapsed/refractory treatment settings
Supplementary Data from CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma
Authors: Cannon Andrew , Thompson Christopher M. , Maurer H. Carlo , Atri Pranita , Bhatia Rakesh , West Sean , Ghersi Dario , Olive Kenneth P. , Kumar Sushil , Batra Surinder K.
Published: April 2023

Details of IPA analysis and the primers sequences used in the manuscript.
Supplementary Figure S2 from TSPO-targeted PET and Optical Probes for the Detection and Localization of Premalignant and Malignant Pancreatic Lesions
Authors: Cohen Allison S. , Li Jun , Hight Matthew R. , McKinley Eliot , Fu Allie , Payne Adria , Liu Yang , Zhang Dawei , Xie Qing , Bai Mingfeng , Ayers Gregory D. , Tantawy Mohammed Noor , Smith Jarrod A. , Revetta Frank , Washington M. Kay , Shi Chanjuan , Merchant Nipun , Manning H. Charles
Published: April 2023

Optical imaging of excised pancreatic lesions using V-1520
Supplementary Table 3 from Functional Genetic Screening Enables Theranostic Molecular Imaging in Cancer
Authors: Perkons Nicholas R. , Johnson Omar , Pilla Gabrielle , Profka Enri , Mercadante Michael , Ackerman Daniel , Gade Terence P.F.
Published: April 2023

This table, organized alphabetically, provides a list of genes, all of which are enzymes, whose activity has been measured by the listed DNP-MRS probe (either directly or indirectly), according to the data provided in Supplementary Table 2.
Supplementary Table 2 from Functional Genetic Screening Enables Theranostic Molecular Imaging in Cancer
Authors: Perkons Nicholas R. , Johnson Omar , Pilla Gabrielle , Profka Enri , Mercadante Michael , Ackerman Daniel , Gade Terence P.F.
Published: April 2023

Each entry in this table consists of a distinct substrate-metabolite pairs, interconverted by the enzyme(s) encoded by the listed gene(s) in a manner that has previously been measured (either directly or indirectly) using the DNP-MRS probe listed.
Figure S2 from Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma
Authors: Casey Dana L. , Wexler Leonard H. , Pitter Kenneth L. , Samstein Robert M. , Slotkin Emily K. , Wolden Suzanne L.
Published: April 2023

TP53 mutational status by age (p=0.05)
Supplementary Figure 2 from Functional Genetic Screening Enables Theranostic Molecular Imaging in Cancer
Authors: Perkons Nicholas R. , Johnson Omar , Pilla Gabrielle , Profka Enri , Mercadante Michael , Ackerman Daniel , Gade Terence P.F.
Published: April 2023

(Rows 1 & 2) Parametric maps of intratumoral metabolite ratios, including lactate-to-pyruvate, alanine-to-pyruvate, and alanine-to-lactate before (row 1) and after (row 2) LDHi. These data demonstrate an increase in intratumoral pyruvate, a decrease in intratumoral lactate, and an increase in intratumoral alanine after LDHi. All maps were generated from the acquisition highlighted in Figure 2A. [P=pyruvate, L=lactate, A=alanine]
Supplementary Figure 1 from Functional Genetic Screening Enables Theranostic Molecular Imaging in Cancer
Authors: Perkons Nicholas R. , Johnson Omar , Pilla Gabrielle , Profka Enri , Mercadante Michael , Ackerman Daniel , Gade Terence P.F.
Published: April 2023

Schematic depicting metabolic pathways that can be analyzed with DNP probes. The background of the figure is a representation of the KEGG human global metabolism map (01100) that was generated in R using Pathview. As in Figure 1A, purple nodes correspond to previously polarized probes. Pink nodes correspond to intermediates that have either been (i) directly visualized after injection of a DNP probe or (ii) have not been directly identified but precede a downstream intermediate that has been directly visualized. Yellow nodes correspond to metabolites that may serve as future molecular imaging probes, as suggested by the data provided in Supplementary Table 1. Dashed lines correspond to an enzyme or group of enzymes connecting DNP-MRS probes and/or intermediates. Colored semi-circles correspond to cancer types that may be imaged with the subjacent, lettered DNP-MRS probe, as described in Supplementary Table 1.
Supplementary Figure S5 from Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells
Authors: Ichikawa Junya , Yoshida Tatsuya , Isser Ariel , Laino Andressa S. , Vassallo Melinda , Woods David , Kim Sojung , Oelke Mathias , Jones Kristi , Schneck Jonathan P. , Weber Jeffrey S.
Published: April 2023

Nano-aAPC expanded CD8+ T-cells targeting gp100.
Supplementary Figure S1 from Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
Authors: Song Yuqin , Zhou Keshu , Zou Dehui , Zhou Jianfeng , Hu Jianda , Yang Haiyan , Zhang Huilai , Ji Jie , Xu Wei , Jin Jie , Lv Fangfang , Feng Ru , Gao Sujun , Guo Haiyi , Zhou Lei , Elstrom Rebecca , Huang Jane , Novotny William , Wei Rachel , Zhu Jun
Published: April 2023

Kaplan-Meier Plot Comparing PFS Among Patients With and Without Prior Rituximab
Supplementary Table from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Authors: Quayle Steven N. , Girgis Natasha , Thapa Dharma R. , Merazga Zohra , Kemp Melissa M. , Histed Alex , Zhao Fan , Moreta Miguel , Ruthardt Paige , Hulot Sandrine , Nelson Alyssa , Kraemer Lauren D. , Beal Dominic R. , Witt Luke , Ryabin Jessica , Soriano Jonathan , Haydock Mark , Spaulding Emily , Ross John F. , Kiener Peter A. , Almo Steven , Chaparro Rodolfo , Seidel Ronald , Suri Anish , Cemerski Saso , Pienta Kenneth J. , Simcox Mary Ellen
Published: April 2023

Supplementary Table 1
Supplemental Figure 5 from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Authors: Quayle Steven N. , Girgis Natasha , Thapa Dharma R. , Merazga Zohra , Kemp Melissa M. , Histed Alex , Zhao Fan , Moreta Miguel , Ruthardt Paige , Hulot Sandrine , Nelson Alyssa , Kraemer Lauren D. , Beal Dominic R. , Witt Luke , Ryabin Jessica , Soriano Jonathan , Haydock Mark , Spaulding Emily , Ross John F. , Kiener Peter A. , Almo Steven , Chaparro Rodolfo , Seidel Ronald , Suri Anish , Cemerski Saso , Pienta Kenneth J. , Simcox Mary Ellen
Published: April 2023

Supplementary Figure 5. Antitumor activity of mCUE-101 in TC-1 tumors.
Supplemental Figure 2 from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Authors: Quayle Steven N. , Girgis Natasha , Thapa Dharma R. , Merazga Zohra , Kemp Melissa M. , Histed Alex , Zhao Fan , Moreta Miguel , Ruthardt Paige , Hulot Sandrine , Nelson Alyssa , Kraemer Lauren D. , Beal Dominic R. , Witt Luke , Ryabin Jessica , Soriano Jonathan , Haydock Mark , Spaulding Emily , Ross John F. , Kiener Peter A. , Almo Steven , Chaparro Rodolfo , Seidel Ronald , Suri Anish , Cemerski Saso , Pienta Kenneth J. , Simcox Mary Ellen
Published: April 2023

Supplementary Figure 2. Flow cytometric characterization of PBMC expansion cultures.
Supplemental Figure 1 from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Authors: Quayle Steven N. , Girgis Natasha , Thapa Dharma R. , Merazga Zohra , Kemp Melissa M. , Histed Alex , Zhao Fan , Moreta Miguel , Ruthardt Paige , Hulot Sandrine , Nelson Alyssa , Kraemer Lauren D. , Beal Dominic R. , Witt Luke , Ryabin Jessica , Soriano Jonathan , Haydock Mark , Spaulding Emily , Ross John F. , Kiener Peter A. , Almo Steven , Chaparro Rodolfo , Seidel Ronald , Suri Anish , Cemerski Saso , Pienta Kenneth J. , Simcox Mary Ellen
Published: April 2023

Supplementary Figure 1. Characterization of CUE-101 binding properties.
Supplementary Table ST1 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial
Authors: Rodriguez Gutierrez Daniel , Jones Chris , Varlet Pascale , Mackay Alan , Warren Daniel , Warmuth-Metz Monika , Aliaga Esther Sánchez , Calmon Raphael , Hargrave Darren R. , Cañete Adela , Massimino Maura , Azizi Amedeo A. , Le Deley Marie-Cécile , Saran Frank , Rousseau Raphael F. , Zahlmann Gudrun , Garcia Josep , Vassal Gilles , Grill Jacques , Morgan Paul S. , Jaspan Tim
Published: April 2023

Raw Study Data
Supplementary Figure SF8 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial
Authors: Rodriguez Gutierrez Daniel , Jones Chris , Varlet Pascale , Mackay Alan , Warren Daniel , Warmuth-Metz Monika , Aliaga Esther Sánchez , Calmon Raphael , Hargrave Darren R. , Cañete Adela , Massimino Maura , Azizi Amedeo A. , Le Deley Marie-Cécile , Saran Frank , Rousseau Raphael F. , Zahlmann Gudrun , Garcia Josep , Vassal Gilles , Grill Jacques , Morgan Paul S. , Jaspan Tim
Published: April 2023

Left thalamic non-enhancing diffuse midline glioma
Supplementary Figure SF7 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial
Authors: Rodriguez Gutierrez Daniel , Jones Chris , Varlet Pascale , Mackay Alan , Warren Daniel , Warmuth-Metz Monika , Aliaga Esther Sánchez , Calmon Raphael , Hargrave Darren R. , Cañete Adela , Massimino Maura , Azizi Amedeo A. , Le Deley Marie-Cécile , Saran Frank , Rousseau Raphael F. , Zahlmann Gudrun , Garcia Josep , Vassal Gilles , Grill Jacques , Morgan Paul S. , Jaspan Tim
Published: April 2023

Incidence of tumor resection in Cerebral versus Midline tumors
Supplementary Figure SF5 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial
Authors: Rodriguez Gutierrez Daniel , Jones Chris , Varlet Pascale , Mackay Alan , Warren Daniel , Warmuth-Metz Monika , Aliaga Esther Sánchez , Calmon Raphael , Hargrave Darren R. , Cañete Adela , Massimino Maura , Azizi Amedeo A. , Le Deley Marie-Cécile , Saran Frank , Rousseau Raphael F. , Zahlmann Gudrun , Garcia Josep , Vassal Gilles , Grill Jacques , Morgan Paul S. , Jaspan Tim
Published: April 2023

Significantly different radiological characteristics of H3 K27M-mutants compared to other Midline wild-type cases
Supplementary Figure SF11 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial
Authors: Rodriguez Gutierrez Daniel , Jones Chris , Varlet Pascale , Mackay Alan , Warren Daniel , Warmuth-Metz Monika , Aliaga Esther Sánchez , Calmon Raphael , Hargrave Darren R. , Cañete Adela , Massimino Maura , Azizi Amedeo A. , Le Deley Marie-Cécile , Saran Frank , Rousseau Raphael F. , Zahlmann Gudrun , Garcia Josep , Vassal Gilles , Grill Jacques , Morgan Paul S. , Jaspan Tim
Published: April 2023

Survival curves of Event Free Survival (EFS) and Overall Survival (OS) of extent of tumor resection